Corporate Social Responsibility
Corporate Social Responsibility (CSR)
Genmab’s commitment to Corporate Social Responsibility (CSR) is anchored in our company’s core purpose “to improve the lives of patients by creating and developing innovative antibody products” and our vision “By 2025 our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies.”
Our vision inspires and motivates us to find new ways to improve healthcare and quality of life for patients and their families. We are committed to creating differentiated antibody products that have the potential to provide new treatment options to patients with life threatening and debilitating diseases. Our efforts to address unmet medical needs have led to the creation and market launch of DARZALEX® (daratumumab) and Arzerra® (ofatumumab) and to the development of a robust pipeline of pre-clinical and clinical products.
We believe we have a responsibility to ensure our actions not only benefit our main stakeholders (patients, shareholders and employees), but also society as a whole. With our core values and vision in mind, being socially responsible is fundamental to the way we do business at Genmab.
When carrying out our business we strive to comply with all relevant laws, standards and guidelines. We also consider the well-being of our employees a top priority, and we minimize our impact on the environment to the extent possible. We have high ethical standards and aim to conduct business with companies and within countries that share our ethics and respect the protection of internationally proclaimed human rights. As we conduct business in a highly regulated industry, we have chosen not to implement a specific human rights policy. It is important to us however, to support and respect the protection of internationally proclaimed human rights through other policies that address responsible supply chain management, ethical procedures, health and safety procedures, and issues regarding access to medicine. Genmab only conducts clinical trials in markets where a drug is planned to become available. Furthermore, Genmab does not employ child labor.
Our CSR Committee is comprised of representatives from our human resources, investor relations & communications, legal, finance, research & development and Executive Management functions. The committee ensures that Genmab carries out its CSR activities effectively and communicates clearly and openly about them.
Genmab publishes its statutory report on CSR for the financial year 2017 cf. Section 99 a of the Danish Financial Statements Act on the company’s website, including additional information about policies, progress made during 2017 and expected activities for 2018. Genmab has adopted a target figure for women in the Board of Directors and a policy regarding the proportion of gender in other management levels of the Genmab group. In accordance with section 99 b of the Danish Financial Statements Act, Genmab discloses the target figure, the policy and current performance in its statutory report on CSR for the financial year 2017.
Click the link below to access Genmab’s statutory report on CSR for the financial year 2017 cf. Section 99a of the Danish Financial Statements Act (“Lovpligtig redegørelse for samfundsansvar, jf. årsregnskabslovens § 99 a”), including additional information about policies, progress made during 2017 and expected activities for 2018.
CSR Report 2017 - English
Policy regarding the Proportion of Gender in other Management Levels of the Genmab group:
Genmab is committed to continue working towards and maintaining equal opportunities for women and men at all management levels in the Genmab group. Genmab encourages talented male and female employees to pursue a career in the company. Genmab regularly conducts employee surveys and employee development interviews to identify barriers – or the perception of barriers – preventing equal opportunities for men and women. In connection with recruitment, including recruitment at management level, it is the policy of the Genmab group to meet the company's needs for employees with the right skills and competences, regardless of gender, age, ethnicity, etc. When choosing between equally qualified candidates, the diversity among the employees shall be taken into consideration, as it is the aim that both genders attain a representation at management levels of at least 40%. In connection with recruitment for managerial positions it must be ensured, where possible, that the candidates invited for interview include both men and women. The company's focus on diversity among its employees, including at management levels, must be visible during recruitment.
The policy may be amended by the Board of Directors and should be interpreted in accordance with applicable equal rights and anti-discrimination legislation in Denmark, in force from time to time.
A Target Figure for the Number of Women in the Board of Directors of Genmab A/S has been established. Click here for more information.